Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL! So that's it. Didn't think you'd identified 400 biotech experts!
Couldn't agree with you more: with thinly-traded stocks it's all about volume.
One note about your post: I'm not trying to bash here (as you yourself say, just trying to be realistic) but the "outside group" that you refer to is Inventya Ltd., a small market research company that BIAD hired.
Just start by entering any of the larger biotech tickers in the Twitter Search box. You'll see the stream. Much of it will be the usual daytraders and wannabees and subscription stock services, no different than message boards. But a few will be discussing aspects of specific drugs, pipelines, testing, the companies themselves at a much more scientific and technical level.
Click on one of those names, go to his full profile, see who he is communicating with. If what he's saying interests you, click Follow. Gradually you'll build up your own stable of knowledgeable experts.
In many sectors, Twitter has replaced/is rapidly replacing emails and message boards as the go-to means of communication. This is especially true in biotech. Probably has something to do with the age of many of the movers & shakers.
I almost never Tweet, but I have a Twitter account (free, takes one minute.) Over the past two years I’ve accumulated about 50 people on my Twitter stream (people whom you follow, their Tweets automatically show up when you go to Twitter.) Mainly research scientists, docs, other folks actually working in the field, some very experienced and knowledgeable analysts, etc.
I just eavesdrop! Half of the technical stuff I don’t understand. But when all of them say a drug or a company is legitimate and a good deal, I do additional DD and often I buy. When all of them say something is a scam, I stay away.
Twitter is a fabulous DD resource.
There was some confusion/miscommunication about two studies being conducted by the Mayo Clinic.
Gupta was actually referring to this study:
https://clinicaltrials.gov/ct2/show/NCT01609283
OT: I can also give you my 2 cents about your Twitter statement, but only if you're interested.
No, it was a misunderstanding, Sanjay Gupta was not referring to BCLI.
I have a good-sized HES position purchased as a long-term hold, but a buyout certainly interests me.
A while back I asked Dew to make a WAG about a possible price, and he rightfully answered that it would depend on oil prices at the time.
Would you care to make a guess? FWIW, to me somewhere around $90 a share seems both fair and realistic.
Repost also: No offense taken, I read the 10K when it came out but you've graciously cleared up my confusion.
I now realize that the independent report being referred to here is being used synonymously with the third-party project referred to in BIAD's recent 10K.
That third-party is Inventya Ltd., a market research company that companies like Bio-AMD hire to do just that: market research.
No offense taken, I read the 10K when it came out but you've graciously cleared up my confusion.
I now realize that the independent report being referred to here is being used synonymously with the third-party project referred to in BIAD's recent 10K.
That third-party is Inventya Ltd., a market research company that companies like Bio-AMD hire to do just that: market research.
I'm a bit confused here: there's an independent report (not a company-supplied PR) coming out that's guaranteed to be positive about the company?
Usually doesn't work that way.
I hear you, sorry for the misunderstanding.
I'm 66, been investing since 1969. We've both seen enough to make our own decisions!
Best of luck!
Jeff Sonnenfeld of Yale and formerly of Harvard is one of the world's leading experts on corporate behavior. He is not your average Joe.
Just perception, of course, but I thought that he got the best of the debate. Much more importantly, I agree with his point: the average investor, after doing careful and extensive due diligence, will do better investing in an individual company rather than blindly following an activist investor—Peltz or anyone else.
Crop- Absolutely no offense meant here (I always hope that other small retail investors do well, it's us against them) but you do realize that following someone does not mean that you automatically buy their picks!
Knowledgeable opinions are worth noting--in stocks and in the rest of life--but that must be only one small part of your due diligence.
Gary
Just curious, IYO what's happening with BIAD?
LOL. I think I can live with that.
My daughter and I just watched it, very funny.
Why didn't he just laugh and say he was exaggerating, that it is certainly poisonous if swallowed but that doesn't mean it causes cancer.
I thought that by definition the placebo is not "real" but the effect is. Therefore, isn't their usage correct?
OT: B.- You're a solid, experienced trader and your results prove that. But as I'm sure you fully realize, you're risking a lot of your street cred on this one stock.
Sincerely hope it works out. -ob
In that part of the world, it's difficult telling one stan from another.
Many years ago, when I taught HS, a student was sure that the capital of the U.S. was in the Northwest. When I gently showed him a map and pointed out Washington D.C., he said seriously, "So that's where the Space Needle is?"
Though not mentioned in this release, I would imagine that security concerns—especially about ISIS—played a part in the decision.
Yep, it's just the way it is. Ameritrade, just for example, will often fill a buy limit order for 10 shares (and I've had one!) before moving the ask up. They want you to bite the bullet and use market orders.
J.- I'm not sure that this says anything about BIAD, per se.
Haven't you seen the same sort of stuff with any small, rather obscure, low-volume stock?
OT: Official rules for True Believer posting-
1. Belief equals evidence, faith equals fact.
2. What we believe is the Truth, everything else is a lie.
3. There is a conspiracy against us; if you deny that there's a conspiracy, you're part of it.
4. Always get the last post. When our opponent gives up in disgust and exasperation, we win.
B.- No sweat, sounds good.
Carp- I didn't mean to be disparaging of you, my apologies if it came off that way. Just thought that perhaps you weren't familiar with the business model of that type of PR company.
One good thing for potential buyers: they're probably not going to do another offering.
My favorite delusion from the Lets-Pretend-It's-An-Ebola-Stock craze was in October when I read a Tweet saying that Google is an Ebola play because people are going to stay home more and surf the net.